Modulation of Interleukin-1 and -18 Mediated Injury in Donation after Circulatory Death Mouse Hearts

Background: Donation after circulatory death donors (DCD) can expand the donor pool for heart transplantation, which primarily depends on brain death donors. Ischemia and reperfusion injury are inherent to the DCD process. We hypothesize that pharmacologic inhibition of interleukin-1 (IL-1) and/or IL-18 is protective to DCD hearts.Materials and methods: Following clinical protocol, in-situ ischemia time in control beating heart donor (CBD) and DCD groups was less than 5 and 40 min, respectively. Wild type (WT) C57Bl6/j, IL-1 receptor type I knockout (IL-1RI-KO), and IL-18 KO mice were used. Hearts were reanimated for 90 min on a Langendorff system with Krebs-Henseleit buffer at 37 degrees C, to assess physiologic parameters. Recombinant IL-1 receptor antagonist (IL-1Ra) and/or IL 18 binding protein (IL-18BP) were added to the Krebs-Henseleit buffer to inhibit IL-1 and/or the IL-18 signaling, respectively.Results: Developed pressure and dP/dt were significantly impaired in the DCD-WT group compared to CBD-WT (P <= 0.05). Troponin release was higher in DCD-WT groups. Functional parameters were preserved, and troponin release was significantly less in the DCD knockout groups. Heart function was improved in DCD groups treated with IL-1Ra or IL18BP compared to the DCD-WT group.Conclusions: Heart function was significantly impaired in the DCD-WT group compared to CBD-WT. Genetic deletion or pharmacologic blockade of IL-1 or IL-18 was protective to DCD hearts. (c) 2020 Elsevier Inc. All rights reserved.